Associated Genetic Biomarkers
NCI Definition: A benign histiocytic tumor that occurs during childhood; it is distinct from Langerhans cell histiocytosis. It is characterized by the presence of lipid-laden, foamy histiocytes and Touton-type giant cells in the dermis. The lesions usually develop during infancy. They consist of cutaneous papules and nodules (most often in the head and neck). It is sometimes associated with deep soft tissues nodules. 
There are 2 clinical trials for juvenile xanthogranuloma, of which 2 are open and 0 are completed or closed. Of the trials that contain juvenile xanthogranuloma as an inclusion criterion, 2 are phase 2 (2 open).
BRAF is the most frequent gene inclusion criterion for juvenile xanthogranuloma clinical trials .
Cobimetinib and vemurafenib are the most common interventions in juvenile xanthogranuloma clinical trials.
Significant Genes in Juvenile Xanthogranuloma
BRAF is an inclusion eligibility criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.